To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens. AbbVie’s Maviret ...

After revenues flattened in the first three months of the year, in the second quarter Gilead saw its total sales fall 6%, largely down to shrinking revenues from its HCV portfolio. Sales shrunk in ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

Hepatitis C Diagnosis and Treatment The hepatitis c diagnosis and treatment market size are predicted to develop because of the factors suc ...

The Vietnam Hepatitis Treatment Market was valued at USD 146.25 million in 2023 and is projected to reach USD 197.35 million by 2029, growing at a CAGR of 5.08% during the forecast period. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...